TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23020996
Drug: Long GnRH
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long GnRH agonist protocol (group I)
Study: 23020996
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist protocol (group II)
Study: 20543747
Drug: CHO drink
Normalized name: G-CSF (CHO cell derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO drink (2:1 glucose-fructose blend; 1.5 g·min)
Study: 20543747
Drug: Plain water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain water (WAT; 675 mL·h)
Study: 9250837
Drug: Discolouration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discolouration of the teeth before treatment
Study: 8039040
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of salbutamol (0.5 mg)
Study: 8039040
Drug: Nebulization of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulization of salbutamol (10 mg)
Study: 8039040
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (i.v. and nebulization)
Study: 23712109
Drug: Control (treatment-as-usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (treatment-as-usual wait list)
Study: 6794081
Drug: Naloxone 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone 0.8 mg
Study: 18075400
Drug: Adenosine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (various doses)
Study: 11498727
Drug: B. monniera
Approvals — FDA: no, EMA: no, PMDA: no
Description: B. monniera (300 mg)
Study: 7601299
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral sumatriptan
Study: 1317294
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg oral aspirin plus 10 mg oral metoclopramide
Study: 27090149
Drug: 8-week vocal
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8-week vocal music therapy treatment group
Study: 21081251
Drug: Sildenafil 20mg
Normalized name: sildenafil 20 MG
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil 20mg thrice daily in addition to bosentan
Study: 17469728
Drug: Rectal artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rectal artesunate 10 mg/kg/day for 3 days followed by oral mefloquine 25 mg/kg
Study: 17469728
Drug: Rectal artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rectal artesunate 20 mg/kg/day for 3 days followed by oral mefloquine 25 mg/kg
Study: 15207886
Drug: Rimostil (57.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimostil (57.2 mg total isoflavones)
Study: 15207886
Drug: Promensil (82
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promensil (82 mg total isoflavones)
Study: 11699249
Drug: Various herbal
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various herbal therapies
Study: 9828735
Drug: Oral vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral vancomycin (15 mg/kg every 8 hours for 7 days)
Study: 16764869
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives initiated at 10 mm follicle diameter
Study: 16764869
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives initiated at 14 mm follicle diameter
Study: 16764869
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives initiated at 18 mm follicle diameter
Study: 11724652
Drug: Ultrasonically nebulized
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonically nebulized distilled water (UNDW) 8 ml
Study: 11724652
Drug: Ultrasonically nebulized
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonically nebulized distilled water (UNDW) 16 ml
Study: 16179403
Drug: N(G)-nitro-L-arginine methyl
Normalized name: methyl L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N(G)-nitro-L-arginine methyl ester (L-NAME)
Study: 11724652
Drug: Ultrasonically nebulized
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonically nebulized distilled water (UNDW) after L-NAME
Study: 9129015
Drug: Tumor-specific idiotype
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor-specific idiotype vaccine (tumor Ig protein coupled to keyhole limpet hemocyanin and emulsified in an immunologic adjuvant)
Study: 9129015
Drug: Tumor-specific idiotype
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor-specific idiotype vaccine
Study: 7895178
Drug: Synthetic human
Normalized name: Synthetic human secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synthetic human parathyroid hormone (PTH 1-38) infusion for 24 hours in 14 healthy females
Study: 31237948
Drug: Antibiotic exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic exposure (from 14 days before to 7 days after vaccination)
Study: 31237948
Drug: Nonexposed to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonexposed to antibiotics
Study: 28739134
Drug: Dextromethorphan (DXM)
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan (DXM) 0.8 mg/kg
Study: 26697137
Drug: n‐3 long
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 long chain polyunsaturated fatty acids (n‐3 LC‐PUFA) enriched enteral formula (98 mg/d eicosapentaenoic acid and 46 mg/d docosahexaenoic acid)
Study: 20801941
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil (OM) 20 mg/day for 3 weeks, uptitrated to OM 40 mg/day, OM/HCTZ 40/12.5 mg/day, and OM/HCTZ 40/25 mg/day
Study: 15845566
Drug: Gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m(2) on days 1 and 8 plus docetaxel 50 mg/m(2) on day 8
Study: 15845566
Drug: Recommended regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended regimen (Gemcitabine 1000 mg/m(2) on days 1 and 8 plus docetaxel 50 mg/m(2) on day 8)
Study: 10609423
Drug: Family-focused psychoeducational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-focused psychoeducational therapy (FFT)
Study: 8690106
Drug: Goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin acetate 3.6 mg once monthly plus 600 mg/d iron
Study: 8690106
Drug: Goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin acetate 3.6 mg once monthly plus placebo iron
Study: 8690106
Drug: Iron alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron alone (600 mg/d)
Study: 6370482
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tablets
Study: 6370482
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg tablets
Study: 6370482
Drug: 2% suspension
Normalized name: Top Cat 2.2% Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% suspension
Study: 24791343
Drug: Sertaconazole 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertaconazole 2% cream
Study: 30264179
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) applied to the quadriceps muscle (850 nm, 5 J per diode)
Study: 24124921
Drug: Intralesional verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional verapamil (ILV) 10 mg weekly for 12 weeks
Study: 24124921
Drug: Intralesional verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional verapamil (ILV) 10 mg weekly for 12 weeks + oral antioxidants (one tablet once a day for 3 months)
Study: 24124921
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (ILV monotherapy)
Study: 20237064
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg beta-carotene
Study: 20237064
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg beta-carotene
Study: 17334775
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg propranolol non-competitive (betaNon)
Study: 7624490
Drug: Butocamide hydrogen
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butocamide hydrogen succinate (BAHS) 600 mg
Study: 7624490
Drug: BAHS 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAHS 600 mg + Nitrazepam 5 mg
Study: 2196359
Drug: Captopril (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (0.9 mg/kg/day)
Study: 359752
Drug: Intramuscular benzathine
Normalized name: Cephapirin Benzathine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular benzathine penicillin G alone
Study: 359752
Drug: Intramuscular benzathine
Normalized name: Cephapirin Benzathine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular benzathine penicillin G combined with hexachlorophene scrubbing
Study: 30669618
Drug: EGCG treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG treatment
Study: 29129251
Drug: Edoxaban 60
Normalized name: edoxaban 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 60 mg (or 30 mg for specific conditions)
Study: 29129251
Drug: Edoxaban and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban and Enoxaparin-warfarin
Study: 10991842
Drug: saquinavir-SGC (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: saquinavir-SGC (1,200 to 1,800 mg) plus ritonavir (100 to 200 mg)
Study: 10991842
Drug: saquinavir-SGC (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: saquinavir-SGC (1,200 mg) three times daily
Study: 28506446
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D treatment
Study: 8969617
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy and bisphosphonates
Study: 3993612
Drug: Nutrient-rich dietary
Normalized name: Votrient
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nutrient-rich dietary supplement (group A)
Study: 23908187
Drug: FIN-RACo+INFL (infliximab
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIN-RACo+INFL (infliximab 3 mg/kg)
Study: 22749176
Drug: Cinnamon extract
Normalized name: Cinnamon Extract
DrugBank: Chinese cinnamon (DB16593)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamon extract (low-dose at 120 mg/d)
Study: 22749176
Drug: Cinnamon extract
Normalized name: Cinnamon Extract
DrugBank: Chinese cinnamon (DB16593)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamon extract (high-dose at 360 mg/d)
Study: 20414661
Drug: Disimpaction for
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disimpaction for the first week and daily laxative (Group A1)
Study: 20414661
Drug: Only daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only daily laxative (Group A2)
Study: 20414661
Drug: Disimpaction for
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disimpaction for the first week and daily laxative (Group B1)
Study: 20414661
Drug: Only daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only daily laxative (Group B2)
Study: 18689552
Drug: Flaxseed oil
Normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed oil (6 g of ALA)
Study: 18689552
Drug: Milled flaxseed
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milled flaxseed (30 g)
Study: 18689552
Drug: Whole flaxseed
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole flaxseed (30 g)
Study: 16422825
Drug: Tadalafil 20
Normalized name: tadalafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 20 mg on-demand treatment
Study: 16422825
Drug: Tadalafil 3
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil 3 times/week treatment
Study: 15540759
Drug: Doxazosin 8
Normalized name: doxazosin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 8 mg with Tadalafil 20 mg
Study: 15540759
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg with Tadalafil 10 mg
Study: 15540759
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg with Tadalafil 20 mg
Study: 24935082
Drug: Medication management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication management plus CBT
Study: 22874692
Drug: Transdermal diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal diclofenac
Study: 11341172
Drug: High levels
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High levels of anti-insulin antibodies (AB1)
Study: 11341172
Drug: Elevated levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated levels of antiidiotypic antibodies (AIAb2)
Study: 11341172
Drug: High levels
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High levels of anti-insulin/NGF Ab1
Study: 30440913
Drug: 1Hz rTMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1Hz rTMS treatment 4 days/week for 3 weeks followed by 30min occupational therapy (OT)
Study: 26784537
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy (CBT) for aggression, 12 sessions
Study: 19093057
Drug: Metronidazole plus
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole plus amoxicillin
Study: 16280177
Drug: Foscarnet (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foscarnet (1 g/day for 4 weeks)
Study: 10048641
Drug: Braun/Oral B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Braun/Oral B D7 powered toothbrush
Study: 10048641
Drug: Oral B
Normalized name: bran ORAL BOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral B Advantage B35 manual toothbrush
Study: 2497168
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium (10 mg)
Study: 2134003
Drug: Beveled preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beveled preparations
Study: 2134003
Drug: Non-beveled preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-beveled preparations
Study: 30557080
Drug: Simultaneous steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous steroid injection after percutaneous A1 pulley release
Study: 792640
Drug: Control (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo or no treatment)
Study: 8895711
Drug: Meperidine 100
Normalized name: meperidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 100 mg IM intraoperative preprocedure
Study: 8895711
Drug: Meperidine 100
Normalized name: meperidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 100 mg IM intraoperative postprocedure
Study: 8895711
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine 60 mg IM intraoperative preprocedure
Study: 8895711
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine 60 mg IM postprocedure
Study: 6343155
Drug: Flurbiprofen 300
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen 300 mg/day
Study: 3291099
Drug: Naproxen 750
Normalized name: naproxen 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 750 mg/day
Study: 29394211
Drug: Other Nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other Nerve Stimulation Therapies (NSTs)
Study: 29394211
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (sham, placebo, or medication only)
Study: 25345982
Drug: RIF‐MMX (2×200
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIF‐MMX (2×200 mg twice daily for 3 days)
Study: 15901742
Drug: Progesterone cream
Normalized name: NATURAL PROGESTERONE CREAM,TOP
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone cream 40 mg twice daily for 12 days
Study: 15901742
Drug: Oral progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral progesterone capsules 200 mg once daily for 12 days
Study: 12556074
Drug: Low calcium
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low calcium dialysate (1.25 mmol/L calcium)
Study: 12556074
Drug: Standard dialysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dialysate (1.75 mmol/L calcium)
Study: 2291881
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of 0.25% bupivacaine plain
Study: 2291881
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of 0.25% bupivacaine with epinephrine 1:200,000
Study: 30106523
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health promotion program in primary schools
Study: 30106523
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health promotion program in primary schools (for high socio-economic status)
Study: 30106523
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health promotion program in primary schools (for low socio-economic status)
Study: 26872721
Drug: Chicory inulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chicory inulin (10g daily for 2 months)
Study: 22180317
Drug: Intense Pulsed
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense Pulsed Light (IPL) treatment with a spectral range of 500-670 and 870-1,200 nm, fluence range of 34-70 J/cm(2), 10 mm × 15 mm spot, pulse width of 10 or 100 mseconds, and 5°C contact cooling.
Study: 22180317
Drug: Pulsed Dye
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed Dye Laser (PDL) treatment at 595 nm, fluence range of 8.1-14.5 J/cm(2), 10 or 7 mm spot, pulse width of 10 or 40 mseconds, with Zimmer air cooling and ultrasound gel.
Study: 8576655
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of sodium cromoglycate
Study: 2338416
Drug: FCE 22101
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCE 22101 intravenously at a dose of 250 mg
Study: 2338416
Drug: FCE 22891
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCE 22891 orally at a dose of 500 mg
Study: 24115827
Drug: LAM +
Normalized name: lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LAM + ADV therapy
Study: 21887230
Drug: G‐CSF treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF treatment (2.5, 5, or 10 μg/kg body weight) for 5 consecutive days
Study: 9692813
Drug: G‐CSF treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF treatment
Study: 21887230
Drug: G‐CSF treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF treatment in combination with routine IV thrombolysis
Study: 18719948
Drug: Nasal O2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal O2 insufflation (4 l/min)
Study: 11563404
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ketoprofen administered locally
Study: 11563404
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg ketoprofen administered locally
Study: 11563404
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg oral capsule of ketoprofen
Study: 11563404
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 10 mg ketoprofen
Study: 7128191
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg meptazinol
Study: 23306584
Drug: Low tidal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tidal volume ventilation (≈3 ml/kg) combined with extracorporeal CO2 elimination
Study: 23306584
Drug: ARDSNet strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARDSNet strategy (≈6 ml/kg) without the extracorporeal device
Study: 17159021
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (twice‐weekly sessions of standard Swedish massage in weeks 1‐4 and once‐weekly sessions in weeks 5‐8)
Study: 9059567
Drug: L-arginine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (30 g in 50 ml of normal saline over 30 minutes) with L-NAME (90 micrograms/kg in 50 ml of normal saline)
Study: 9059567
Drug: Glucose (0.33
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (0.33 g/kg body weight in a bolus) with L-NAME (90 micrograms/kg in 50 ml of normal saline)
Study: 9059567
Drug: Glucose (0.33
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (0.33 g/kg body weight in a bolus) with saline
Study: 9059567
Drug: L-NAME (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NAME (90 micrograms/kg in 50 ml of normal saline) alone
Study: 7956277
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion (5 micrograms/kg/min i.v.)
Study: 2885637
Drug: Adjuvant tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant tamoxifen 20 mg daily for 5 years